Helicobacter pylori proteins and membrane components (H. pylori components)

Helicobacter pylori is a Gram-negative, microaerophilic bacterium that colonizes the human gastric mucosa, leading to chronic inflammation and increased risk of malignancy (StatPearls, 2023). This target entry represents a collective group of bacterial components, including enzymes like urease, which is vital for acid neutralization, and adhesins such as BabA that facilitate epithelial attachment (Nature Reviews Disease Primers, 2017). Virulence factors like CagA and VacA are also included, as they disrupt host cell signaling and induce apoptosis, contributing to peptic ulcer disease and gastric adenocarcinoma (UniProt, 2024). Therapeutic strategies against these components involve multi-drug regimens, typically combining antibiotics like clarithromycin and amoxicillin with proton pump inhibitors to achieve eradication (Mayo Clinic, 2023). The primary challenge in targeting these bacterial components is the rising global prevalence of antibiotic resistance, particularly to macrolides and fluoroquinolones (World Journal of Gastroenterology, 2014).

Other names

H. pylori antigensHelicobacter pylori proteomeH. pylori virulence factorsH. pylori cell wall and intracellular proteins

Drugs targeting these components act by inhibiting bacterial cell wall synthesis (beta-lactams), disrupting protein synthesis at the 30S or 50S ribosomal subunits (tetracyclines, macrolides), or causing DNA damage through reductive activation (nitroimidazoles) (StatPearls, 2023).